Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy

References

• Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:33. doi:10.1186/s40659-017-0140-9
   PubMed Web of Science ®Google Scholar
• Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: from early detection to new therapies. Radiologia. 2017;59:368–379. doi:10.1016/j.rx.2017.06.003
   PubMed Web of Science ®Google Scholar
• Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: a systematic review. Breast. 2022;64:85–99. doi:10.1016/j.breast.2022.04.003
   PubMed Web of Science ®Google Scholar
• Subik K, Lee J-F, Baxter L, et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer. 2010;4:35–41.
   PubMedGoogle Scholar
• Mota ADL, Evangelista AF, Macedo T, et al. Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers. Oncol Lett. 2017;13(6):4708–4712. doi:10.3892/ol.2017.6093
   PubMed Web of Science ®Google Scholar
• Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708–1728. doi:10.1016/j.cell.2023.01.040
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15(1):121. doi:10.1186/s13045-022-01341-0
   PubMed Web of Science ®Google Scholar
• Yallapu MM, Jaggi M, Chauhan SC. Curcumin nanomedicine: a road to cancer therapeutics. Curr Pharm Des. 2013;19:1994–2010. doi:10.2174/138161213805289219
   PubMed Web of Science ®Google Scholar
• Yadav N, Parveen S, Banerjee M. Potential of nano-phytochemicals in cervical cancer therapy. Clin Chim Acta. 2020;505:60–72. doi:10.1016/j.cca.2020.01.035
   PubMed Web of Science ®Google Scholar
• Pradhan D, Biswasroy P, Sahu A, et al. Recent advances in herbal nanomedicines for cancer treatment. Curr Mol Pharmacol. 2021;14(3):292–305. doi:10.2174/1874467213666200525010624
   PubMed Web of Science ®Google Scholar
• Rauf A, Imran M, Butt MS, et al. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58(9):1428–1447. doi:10.1080/10408398.2016.1263597
   PubMed Web of Science ®Google Scholar
• Mirahmadi M, Azimi-Hashemi S, Saburi E, et al. Potential inhibitory effect of lycopene on prostate cancer. Biomed Pharmacother. 2020;129:110459. doi:10.1016/j.biopha.2020.110459
   PubMed Web of Science ®Google Scholar
• Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398. doi:10.1016/j.phrs.2019.104398
   PubMed Web of Science ®Google Scholar
• Albalawi AE, Alanazi AD, Sharifi I, Ezzatkhah F. A systematic review of curcumin and its derivatives as valuable sources of antileishmanial agents. Acta Parasitol. 2021;66(3):797–811. doi:10.1007/s11686-021-00351-1
   PubMed Web of Science ®Google Scholar
• Mahmoudvand H, Pakravanan M, Aflatoonian MR, et al. Efficacy and safety of Curcuma longa essential oil to inactivate hydatid cyst protoscoleces. BMC Complement Altern Med. 2019;19:187. doi:10.1186/s12906-019-2527-3
   PubMed Web of Science ®Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35(10):3365–3383. doi:10.1016/j.biomaterials.2013.12.090
   PubMed Web of Science ®Google Scholar
• Rashwan AK, Karim N, Xu Y, et al. An updated and comprehensive review on the potential health effects of curcumin-encapsulated micro/nanoparticles. Crit Rev Food Sci Nutr. 2022:1–21. doi:10.1080/10408398.2022.2070906
   PubMed Web of Science ®Google Scholar
• Pooresmaeil M, Namazi H. Facile preparation of pH-sensitive chitosan microspheres for delivery of curcumin; characterization, drug release kinetics and evaluation of anticancer activity. Int J Biol Macromol. 2020;162:501–511. doi:10.1016/j.ijbiomac.2020.06.183
   PubMed Web of Science ®Google Scholar
• Fang Z, Pan S, Gao P, et al. Stimuli-responsive charge-reversal nano drug delivery system: the promising targeted carriers for tumor therapy. Int J Pharm. 2020;575:118841. doi:10.1016/j.ijpharm.2019.118841
   PubMed Web of Science ®Google Scholar
• Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24(3):179–191. doi:10.3109/1061186x.2015.1051049
   PubMed Web of Science ®Google Scholar
• Li B, Shao H, Gao L, et al. Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review. Drug Deliv. 2022;29(1):2130–2161. doi:10.1080/10717544.2022.2094498
   PubMed Web of Science ®Google Scholar
• Raj S, Khurana S, Choudhari R, et al. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin Cancer Biol. 2021;69:166–177. doi:10.1016/j.semcancer.2019.11.002
   PubMed Web of Science ®Google Scholar
• Zhang G, Zeng X, Li P. Nanomaterials in cancer-therapy drug delivery system. J Biomed Nanotechnol. 2013;9(5):741–750. doi:10.1166/jbn.2013.1583
   PubMed Web of Science ®Google Scholar
• Cisterna BA, Kamaly N, Choi WI, et al. Targeted nanoparticles for colorectal cancer. Nanomedicine. 2016;11(18):2443–2456. doi:10.2217/nnm-2016-0194
   PubMed Web of Science ®Google Scholar
• Ahmad A, Khan F, Mishra RK, Khan R. Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting. J Med Chem. 2019;62(23):10475–10496. doi:10.1021/acs.jmedchem.9b00511
   PubMed Web of Science ®Google Scholar
• Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Pers Ther. 2019;34(1). doi:10.1515/dmpt-2018-0032
   PubMedGoogle Scholar
• Janjua KA, Shehzad A, Shahzad R, Islam SU, Islam MU. Nanocurcumin: a double-edged sword for microcancers. Curr Pharm Des. 2020;26(45):5783–5792. doi:10.2174/1381612826666201118100045
   PubMed Web of Science ®Google Scholar
• Hussain Y, Islam L, Khan H, et al. Curcumin–cisplatin chemotherapy: a novel strategy in promoting chemotherapy efficacy and reducing side effects. Phytother Res. 2021;35(12):6514–6529. doi:10.1002/ptr.7225
   PubMed Web of Science ®Google Scholar
• Kabir MT, Rahman MH, Akter R, et al. Potential role of curcumin and its nanoformulations to treat various types of cancers. Biomolecules. 2021;11(3):392. doi:10.3390/biom11030392
   PubMed Web of Science ®Google Scholar
• Maleki Dizaj S, Alipour M, Dalir Abdolahinia E, et al. Curcumin nanoformulations: beneficial nanomedicine against cancer. Phytother Res. 2022;36(3):1156–1181. doi:10.1002/ptr.7389
   PubMed Web of Science ®Google Scholar
• Mahmoudi A, Kesharwani P, Majeed M, Teng Y, Sahebkar A. Recent advances in nanogold as a promising nanocarrier for curcumin delivery. Colloids Surf B Biointerfaces. 2022;215:112481. doi:10.1016/j.colsurfb.2022.112481
   PubMed Web of Science ®Google Scholar
• Priyadarsini KI. The chemistry of curcumin: from extraction to therapeutic agent. Molecules. 2014;19(12):20091–20112. doi:10.3390/molecules191220091
   PubMed Web of Science ®Google Scholar
• Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 2019;20(5):1033. doi:10.3390/ijms20051033
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511–545. doi:10.1089/ars.2007.1769
   PubMed Web of Science ®Google Scholar
• Kotha RR, Luthria DL. Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects. Molecules. 2019;24(16):2930. doi:10.3390/molecules24162930
   PubMed Web of Science ®Google Scholar
• Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2014;66(1):222–307. doi:10.1124/pr.110.004044
   PubMed Web of Science ®Google Scholar
• Payton F, Sandusky P, Alworth WL. NMR study of the solution structure of curcumin. J Nat Prod. 2007;70(2):143–146. doi:10.1021/np060263s
   PubMed Web of Science ®Google Scholar
• Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin. J Med Chem. 2017;60(5):1620–1637. doi:10.1021/acs.jmedchem.6b00975
   PubMed Web of Science ®Google Scholar
• Mari M, Carrozza D, Ferrari E, Asti M. Applications of radiolabelled curcumin and its derivatives in medicinal chemistry. Int J Mol Sci. 2021;22(14):7410. doi:10.3390/ijms22147410
   PubMed Web of Science ®Google Scholar
• Schneider C, Gordon ON, Edwards RL, Luis PB. Degradation of curcumin: from mechanism to biological implications. J Agric Food Chem. 2015;63(35):7606–7614. doi:10.1021/acs.jafc.5b00244
   PubMed Web of Science ®Google Scholar
• Feng T, Wei Y, Lee RJ, Zhao L. Liposomal curcumin and its application in cancer. Int J Nanomedicine. 2017;12:6027–6044. doi:10.2147/ijn.S132434
   PubMed Web of Science ®Google Scholar
• Zhai B, Zeng Y, Zeng Z, et al. Drug delivery systems for elemene, its main active ingredient β-elemene, and its derivatives in cancer therapy. Int J Nanomedicine. 2018;13:6279–6296. doi:10.2147/ijn.S174527
   PubMed Web of Science ®Google Scholar
• Rein MJ, Renouf M, Cruz-Hernandez C, et al. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol. 2013;75(3):588–602. doi:10.1111/j.1365-2125.2012.04425.x
   PubMed Web of Science ®Google Scholar
• Dei Cas M, Ghidoni R. Dietary curcumin: correlation between bioavailability and health potential. Nutrients. 2019;11(9):2147. doi:10.3390/nu11092147
   PubMed Web of Science ®Google Scholar
• Lopresti AL. The problem of curcumin and its bioavailability: could its gastrointestinal influence contribute to its overall health-enhancing effects? Adv Nutr. 2018;9(1):41–50. doi:10.1093/advances/nmx011
   PubMed Web of Science ®Google Scholar
• Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001;61(3):1058–1064.
   PubMed Web of Science ®Google Scholar
• Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1411–1417. doi:10.1158/1055-9965.Epi-07-2693
   PubMed Web of Science ®Google Scholar
• Cheng D, Li W, Wang L, et al. Pharmacokinetics, pharmacodynamics, and PKPD modeling of curcumin in regulating antioxidant and epigenetic gene expression in healthy human volunteers. Mol Pharm. 2019;16(5):1881–1889. doi:10.1021/acs.molpharmaceut.8b01246
   PubMedGoogle Scholar
• Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053–1064. doi:10.1016/j.biotechadv.2014.04.004
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–818. doi:10.1021/mp700113r
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Bordoloi D, Padmavathi G, et al. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325–1348. doi:10.1111/bph.13621
   PubMed Web of Science ®Google Scholar
• Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev. 2002;11:105–111.
   PubMed Web of Science ®Google Scholar
• Asai A, Miyazawa T. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. Life Sci. 2000;67(23):2785–2793. doi:10.1016/s0024-3205(00)00868-7
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. doi:10.1073/pnas.191367098
   PubMed Web of Science ®Google Scholar
• Wheatley DN. A new journal – “theoretical biology and medical modelling”. Theor Biol Med Model. 2005;2(1):21. doi:10.1186/1742-4682-2-21
   PubMedGoogle Scholar
• Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in treating breast cancer: a review. J Lab Autom. 2016;21:723–731. doi:10.1177/2211068216655524
   PubMedGoogle Scholar
• Sethiya A, Agarwal DK, Agarwal S. Current trends in drug delivery system of curcumin and its therapeutic applications. Mini Rev Med Chem. 2020;20:1190–1232. doi:10.2174/1389557520666200429103647
   PubMed Web of Science ®Google Scholar
• Obeid MA, Alsaadi M, Aljabali AA. Recent updates in curcumin delivery. J Liposome Res. 2022;1–12. doi:10.1080/08982104.2022.2086567
   Web of Science ®Google Scholar
• Ströfer M, Jelkmann W, Depping R. Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther Onkol. 2011;187:393–400. doi:10.1007/s00066-011-2248-0
   PubMed Web of Science ®Google Scholar
• Altenburg JD, Bieberich AA, Terry C, et al. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer. 2011;11(1):149. doi:10.1186/1471-2407-11-149
   PubMed Web of Science ®Google Scholar
• Shao Z-M, Shen -Z-Z, Liu C-H, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int J Oncol. 2002;98(2):234–240. doi:10.1002/ijc.10183
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer. 2007;31:243–305. doi:10.1016/j.currproblcancer.2007.04.001
   PubMed Web of Science ®Google Scholar
• Ke C-S, Liu H-S, Yen C-H, et al. Curcumin-induced aurora-a suppression not only causes mitotic defect and cell cycle arrest but also alters chemosensitivity to anticancer drugs. J Nutr Biochem. 2014;25(5):526–539. doi:10.1016/j.jnutbio.2014.01.003
   PubMed Web of Science ®Google Scholar
• Zhou Q-M, Wang X-F, Liu X-J, et al. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. Acta Pharmacol Sin. 2011;32(11):1402–1410. doi:10.1038/aps.2011.97
   PubMed Web of Science ®Google Scholar
• Kim J-M, Noh E-M, Kwon K-B, et al. Curcumin suppresses the TPA-induced invasion through inhibition of PKCα-dependent MMP-expression in MCF-7 human breast cancer cells. Phytomedicine. 2012;19(12):1085–1092. doi:10.1016/j.phymed.2012.07.002
   PubMed Web of Science ®Google Scholar
• Hassan ZK, Daghestani MH. Curcumin effect on MMPs and TIMPs genes in a breast cancer cell line. Asian Pac J Cancer Prev. 2012;13(7):3259–3264. doi:10.7314/apjcp.2012.13.7.3259
   PubMed Web of Science ®Google Scholar
• Bachmeier BE, Mohrenz IV, Mirisola V, et al. Curcumin downregulates the inflammatory cytokines CXCL1 and −2 in breast cancer cells via NFkappaB. Carcinogenesis. 2008;29(4):779–789. doi:10.1093/carcin/bgm248
   PubMed Web of Science ®Google Scholar
• Xia Y, Jin L, Zhang B, et al. The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci. 2007;80(23):2161–2169. doi:10.1016/j.lfs.2007.04.008
   PubMed Web of Science ®Google Scholar
• Narasimhan SR, Yang L, Gerwin BI, Broaddus VC. Resistance of pleural mesothelioma cell lines to apoptosis: relation to expression of Bcl-2 and Bax. Am J Physiol. 1998;275(1):L165–171. doi:10.1152/ajplung.1998.275.1.L165
   PubMedGoogle Scholar
• Nagaraju GP, Zhu S, Ko JE, et al. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett. 2015;357(2):557–565. doi:10.1016/j.canlet.2014.12.007
   PubMed Web of Science ®Google Scholar
• Abadi AJ, Mirzaei S, Mahabady MK, et al. Curcumin and its derivatives in cancer therapy: potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res. 2022;36(1):189–213. doi:10.1002/ptr.7305
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Md Sakib Hossain D, Mohanty S, et al. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol. 2010;7(4):306–315. doi:10.1038/cmi.2010.11
   PubMed Web of Science ®Google Scholar
• Abbasalizadeh F, Alizadeh E, Bagher Fazljou SM, Torbati M, Akbarzadeh A. Anticancer effect of alginate-chitosan hydrogel loaded with curcumin and chrysin on lung and breast cancer cell lines. Curr Drug Deliv. 2022;19:600–613. doi:10.2174/1567201818666210813142007
   PubMed Web of Science ®Google Scholar
• Abbasi S, Kajimoto K, Harashima H. Critical parameters dictating efficiency of membrane-mediated drug transfer using nanoparticles. Int J Pharm. 2018;553(1–2):398–407. doi:10.1016/j.ijpharm.2018.10.042
   PubMedGoogle Scholar
• Jafarinejad-Farsangi S, Hashemi MS, Yazdi Rouholamini SE, et al. Curcumin loaded on graphene nanosheets induced cell death in mammospheres from MCF-7 and primary breast tumor cells. Biomed Mater. 2021;16(4):045040. doi:10.1088/1748-605X/ac0400
   Web of Science ®Google Scholar
• Jahanshahi M, Kowsari E, Haddadi-Asl V, et al. Sericin grafted multifunctional curcumin loaded fluorinated graphene oxide nanomedicines with charge switching properties for effective cancer cell targeting. Int J Pharm. 2019;572:118791. doi:10.1016/j.ijpharm.2019.118791
   PubMedGoogle Scholar
• Jaisamut P, Wiwattanawongsa K, Graidist P, Sangsen Y, Wiwattanapatapee R. Enhanced oral bioavailability of curcumin using a supersaturatable self-microemulsifying system incorporating a hydrophilic polymer; in vitro and in vivo investigations. AAPS PharmSciTech. 2018;19(2):730–740. doi:10.1208/s12249-017-0857-3
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Mishra P. Co-delivery of curcumin and serratiopeptidase in HeLa and MCF-7 cells through nanoparticles show improved anti-cancer activity. Mater Sci Eng C Mater Biol Appl. 2018;92:673–684. doi:10.1016/j.msec.2018.07.025
   PubMed Web of Science ®Google Scholar
• Bao C, Jiang P, Chai J, et al. The delivery of sensitive food bioactive ingredients: absorption mechanisms, influencing factors, encapsulation techniques and evaluation models. Food Res Int. 2019;120:130–140. doi:10.1016/j.foodres.2019.02.024
   PubMed Web of Science ®Google Scholar
• Du M, Ouyang Y, Meng F, et al. Nanotargeted agents: an emerging therapeutic strategy for breast cancer. Nanomedicine. 2019;14(13):1771–1786. doi:10.2217/nnm-2018-0481
   PubMed Web of Science ®Google Scholar
• Fraguas-Sánchez AI, Lozza I, Torres-Suárez AI. Actively targeted nanomedicines in breast cancer: from pre-clinal investigation to clinic. Cancers. 2022;14(5):1198. doi:10.3390/cancers14051198
   PubMed Web of Science ®Google Scholar
• Ganesan K, Wang Y, Gao F, et al. Targeting engineered nanoparticles for breast cancer therapy. Pharmaceutics. 2021;13(11):1829. doi:10.3390/pharmaceutics13111829
   PubMed Web of Science ®Google Scholar
• Alqaraghuli HGJ, Kashanian S, Rafipour R. A review on targeting nanoparticles for breast cancer. Curr Pharm Biotechnol. 2019;20(13):1087–1107. doi:10.2174/1389201020666190731130001
   PubMed Web of Science ®Google Scholar
• Dong Z, Cui M-Y, Peng Z, et al. Nanoparticles for colorectal cancer targeted drug delivery and MR imaging: current situation and perspectives. Curr Cancer Drug Targets. 2016;16(6):536–550. doi:10.2174/1568009616666151130214442
   PubMed Web of Science ®Google Scholar
• Gary-Bobo M, Vaillant O, Maynadier M, et al. Targeting multiplicity: the key factor for anti-cancer nanoparticles. Curr Med Chem. 2013;20(15):1946–1955. doi:10.2174/0929867311320150002
   PubMed Web of Science ®Google Scholar
• Grinberg S, Linder C, Heldman E. Progress in lipid-based nanoparticles for cancer therapy. Crit Rev Oncog. 2014;19(3–4):247–260. doi:10.1615/critrevoncog.2014011815
   PubMedGoogle Scholar
• Sun T, Zhang YS, Pang B, et al. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem. 2014;53(46):12320–12364. doi:10.1002/anie.201403036
   Google Scholar
• Hamano N, Böttger R, Lee SE, et al. Robust microfluidic technology and new lipid composition for fabrication of curcumin-loaded liposomes: effect on the anticancer activity and safety of cisplatin. Mol Pharm. 2019;16(9):3957–3967. doi:10.1021/acs.molpharmaceut.9b00583
   PubMed Web of Science ®Google Scholar
• Hasan M, Elkhoury K, Belhaj N, et al. Growth-inhibitory effect of chitosan-coated liposomes encapsulating curcumin on MCF-7 breast cancer cells. Mar Drugs. 2020;18(4):217. doi:10.3390/md18040217
   PubMed Web of Science ®Google Scholar
• Li R, Deng L, Cai Z, et al. Liposomes coated with thiolated chitosan as drug carriers of curcumin. Mater Sci Eng C Mater Biol Appl. 2017;80:156–164. doi:10.1016/j.msec.2017.05.136
   PubMed Web of Science ®Google Scholar
• Mahmoudi R, Hassandokht F, Ardakani MT, et al. Intercalation of curcumin into liposomal chemotherapeutic agent augments apoptosis in breast cancer cells. J Biomater Appl. 2021;35(8):1005–1018. doi:10.1177/0885328220976331
   PubMed Web of Science ®Google Scholar
• Karabasz A, Lachowicz D, Karewicz A, et al. Analysis of toxicity and anticancer activity of micelles of sodium alginate-curcumin. Int J Nanomedicine. 2019;14:7249–7262. doi:10.2147/ijn.S213942
   PubMed Web of Science ®Google Scholar
• Muddineti OS, Vanaparthi A, Rompicharla SVK, et al. Cholesterol and vitamin E-conjugated PEGylated polymeric micelles for efficient delivery and enhanced anticancer activity of curcumin: evaluation in 2D monolayers and 3D spheroids. Artif Cells, Nanomed Biotechnol. 2018;46(sup1):773–786. doi:10.1080/21691401.2018.1435551
   PubMed Web of Science ®Google Scholar
• Sarika PR, Nirmala RJ. Curcumin loaded gum Arabic aldehyde-gelatin nanogels for breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016;65:331–337. doi:10.1016/j.msec.2016.04.044
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Bui QA, Nguyen HHN, et al. Curcuminoid co-loading platinum heparin-poloxamer P403 Nanogel increasing effectiveness in antitumor activity. Gels. 2022;8(1):59. doi:10.3390/gels8010059
   PubMed Web of Science ®Google Scholar
• Wang W, Chen T, Xu H, et al. Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules. 2018;23. doi:10.3390/molecules23071578
   Web of Science ®Google Scholar
• Fathy Abd-Ellatef G-E, Gazzano E, Chirio D, et al. Curcumin-loaded solid lipid nanoparticles bypass P-glycoprotein mediated doxorubicin resistance in triple negative breast cancer cells. Pharmaceutics. 2020;12(2):96. doi:10.3390/pharmaceutics12020096
   PubMed Web of Science ®Google Scholar
• Meena R, Kumar S, Kumar R, Gaharwar US, Rajamani P. PLGA-CTAB curcumin nanoparticles: fabrication, characterization and molecular basis of anticancer activity in triple negative breast cancer cell lines (MDA-MB-231 cells). Biomed Pharmacother. 2017;94:944–954. doi:10.1016/j.biopha.2017.07.151
   PubMed Web of Science ®Google Scholar
• Vakilinezhad MA, Amini A, Dara T, Alipour S. Methotrexate and Curcumin co-encapsulated PLGA nanoparticles as a potential breast cancer therapeutic system: in vitro and in vivo evaluation. Colloids Surf B Biointerfaces. 2019;184:110515. doi:10.1016/j.colsurfb.2019.110515
   PubMed Web of Science ®Google Scholar
• Abdel-Hakeem MA, Mongy S, Hassan B, Tantawi OI, Badawy I. Curcumin loaded chitosan-protamine nanoparticles revealed antitumor activity via suppression of NF-κB, proinflammatory cytokines and Bcl-2 gene expression in the breast cancer cells. J Pharm Sci. 2021;110(9):3298–3305. doi:10.1016/j.xphs.2021.06.004
   PubMed Web of Science ®Google Scholar
• Kamalabadi-Farahani M, Vasei M, Ahmadbeigi N, et al. Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S1011–s1021. doi:10.1080/21691401.2018.1527345
   PubMed Web of Science ®Google Scholar
• Lin J, Cai Q, Tang Y, et al. PEGylated lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: design, characterization and its cytotoxic effect. Int J Pharm. 2018;536(1):272–282. doi:10.1016/j.ijpharm.2017.10.043
   PubMedGoogle Scholar
• Khandelwal P, Alam A, Choksi A, Chattopadhyay S, Poddar P. Retention of anticancer activity of curcumin after conjugation with fluorescent gold quantum clusters: an in vitro and in vivo xenograft study. ACS omega. 2018;3(5):4776–4785. doi:10.1021/acsomega.8b00113
   PubMed Web of Science ®Google Scholar
• Vemuri SK, Halder S, Banala RR, et al. Modulatory effects of biosynthesized gold nanoparticles conjugated with curcumin and paclitaxel on tumorigenesis and metastatic pathways-in vitro and in vivo studies. Int J Mol Sci. 2022;23(4):2150. doi:10.3390/ijms23042150
   PubMed Web of Science ®Google Scholar
• Bharmoria P, Bisht M, Gomes MC, et al. Protein-olive oil-in-water nanoemulsions as encapsulation materials for curcumin acting as anticancer agent towards MDA-MB-231 cells. Sci Rep. 2021;11(1):9099. doi:10.1038/s41598-021-88482-3
   PubMed Web of Science ®Google Scholar
• Kazi M, Nasr F, Noman O, et al. Development, characterization optimization, and assessment of curcumin-loaded bioactive self-nanoemulsifying formulations and their inhibitory effects on human breast cancer MCF-7 cells. Pharmaceutics. 2020;12(11):1107. doi:10.3390/pharmaceutics12111107
   PubMed Web of Science ®Google Scholar
• Aqil F, Munagala R, Jeyabalan J, Agrawal AK, Gupta R. Exosomes for the enhanced tissue bioavailability and efficacy of curcumin. AAPS J. 2017;19(6):1691–1702. doi:10.1208/s12248-017-0154-9
   PubMed Web of Science ®Google Scholar
• González-Sarrías A, Iglesias-Aguirre CE, Cortés-Martín A, et al. Milk-derived exosomes as nanocarriers to deliver curcumin and resveratrol in breast tissue and enhance their anticancer activity. Int J Mol Sci. 2022;23(5):2860. doi:10.3390/ijms23052860
   PubMed Web of Science ®Google Scholar
• Galisteo-González F, Molina-Bolívar JA, Navarro SA, et al. Albumin-covered lipid nanocapsules exhibit enhanced uptake performance by breast-tumor cells. Colloids Surf B Biointerfaces. 2018;165:103–110. doi:10.1016/j.colsurfb.2018.02.024
   PubMed Web of Science ®Google Scholar
• De D, Das CK, Mandal D, et al. Curcumin complexed with graphene derivative for breast cancer therapy. ACS Appl Bio Mater. 2020;3(9):6284–6296. doi:10.1021/acsabm.0c00771
   PubMedGoogle Scholar
• Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592–599. doi:10.1016/j.tips.2009.08.004
   PubMed Web of Science ®Google Scholar
• Chapman HD, Rathinam T. Focused review: the role of drug combinations for the control of coccidiosis in commercially reared chickens. Int J Parasitol Drugs Drug Resist. 2022;18:32–42. doi:10.1016/j.ijpddr.2022.01.001
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. Circ Res. 2019;124(7):1113–1123. doi:10.1161/circresaha.118.313294
   PubMed Web of Science ®Google Scholar
• van Hasselt JGC, Iyengar R. Systems pharmacology: defining the interactions of drug combinations. Annu Rev Pharmacol Toxicol. 2019;59(1):21–40. doi:10.1146/annurev-pharmtox-010818-021511
   PubMedGoogle Scholar
• Walker AJ. Regulatory considerations in the development of radiation-drug combinations. Int J Radiat Oncol Biol Phys. 2021;111(5):1140–1144. doi:10.1016/j.ijrobp.2021.07.1710
   PubMed Web of Science ®Google Scholar
• Wu Y-L, Li Z. The perspectives of using unimolecular micelles in nanodrug formulation. Ther Deliv. 2019;10(6):333–335. doi:10.4155/tde-2019-0033
   PubMed Web of Science ®Google Scholar
• Zhang L, Shi D, Shi C, Kaneko T, Chen M. Supramolecular micellar drug delivery system based on multi-arm block copolymer for highly effective encapsulation and sustained-release chemotherapy. J Mater Chem B. 2019;7(37):5677–5687. doi:10.1039/c9tb01221d
   PubMed Web of Science ®Google Scholar
• Wan Z, Zheng R, Moharil P, et al. Polymeric micelles in cancer immunotherapy. Molecules. 2021;26(5):1220. doi:10.3390/molecules26051220
   PubMed Web of Science ®Google Scholar
• Costa D, Santo D, Domingues C, et al. Recent advances in peptide-targeted micelleplexes: current developments and future perspectives. Int J Pharm. 2021;597:120362. doi:10.1016/j.ijpharm.2021.120362
   PubMedGoogle Scholar
• Pereira P, Barreira M, Queiroz JA, et al. Smart micelleplexes as a new therapeutic approach for RNA delivery. Expert Opin Drug Deliv. 2017;14(3):353–371. doi:10.1080/17425247.2016.1214567
   PubMed Web of Science ®Google Scholar
• Dong S, Jiang Y, Qin G, Liu L, Zhao H. Methionine-based pH and oxidation dual-responsive block copolymer: synthesis and fabrication of protein nanogels. Biomacromolecules. 2020;21(10):4063–4075. doi:10.1021/acs.biomac.0c00879
   PubMed Web of Science ®Google Scholar
• Wang H, Gao L, Fan T, et al. Strategic design of intelligent-responsive nanogel carriers for cancer therapy. ACS Appl Mater Interfaces. 2021;13(46):54621–54647. doi:10.1021/acsami.1c13634
   PubMed Web of Science ®Google Scholar
• Ferreira Soares DC, Domingues SC, Viana DB, Tebaldi ML. Polymer-hybrid nanoparticles: current advances in biomedical applications. Biomed Pharmacother. 2020;131:110695. doi:10.1016/j.biopha.2020.110695
   PubMed Web of Science ®Google Scholar
• Nicolas J, Couvreur P. Les nanoparticules polymères pour la délivrance de principes actifs anticancéreux [Polymer nanoparticles for the delivery of anticancer drug]. Med Sci. 2017;33(1):11–17. French. doi:10.1051/medsci/20173301003
   Google Scholar
• Grill AE, Shahani K, Koniar B, Panyam J. Chemopreventive efficacy of curcumin-loaded PLGA microparticles in a transgenic mouse model of HER-2-positive breast cancer. Drug Deliv Transl Res. 2018;8(2):329–341. doi:10.1007/s13346-017-0377-4
   PubMed Web of Science ®Google Scholar
• Sheikh A, Md S, Alhakamy NA, Kesharwani P. Recent development of aptamer conjugated chitosan nanoparticles as cancer therapeutics. Int J Pharm. 2022;620:121751. doi:10.1016/j.ijpharm.2022.121751
   PubMedGoogle Scholar
• Ryu JH, Yoon HY, Sun IC, Kwon IC, Kim K. Tumor-targeting glycol chitosan nanoparticles for cancer heterogeneity. Adv Mater. 2020;32(51):e2002197. doi:10.1002/adma.202002197
   PubMed Web of Science ®Google Scholar
• Rizeq BR, Younes NN, Rasool K, Nasrallah GK. Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles. Int J Mol Sci. 2019;20(22):5776. doi:10.3390/ijms20225776
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016;28:59–69. doi:10.1097/gco.0000000000000239
   PubMed Web of Science ®Google Scholar
• Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett. 2009;285(1):1–5. doi:10.1016/j.canlet.2009.02.029
   PubMed Web of Science ®Google Scholar
• Chen C, Sun W, Wang X, Wang Y, Wang P. Rational design of curcumin loaded multifunctional mesoporous silica nanoparticles to enhance the cytotoxicity for targeted and controlled drug release. Mater Sci Eng C Mater Biol Appl. 2018;85:88–96. doi:10.1016/j.msec.2017.12.007
   PubMed Web of Science ®Google Scholar
• Shah S, Famta P, Bagasariya D, et al. Tuning mesoporous silica nanoparticles in novel avenues of cancer therapy. Mol Pharm. 2022;19(12):4428–4452. doi:10.1021/acs.molpharmaceut.2c00374
   PubMedGoogle Scholar
• Gao J, Fan K, Jin Y, et al. PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden. Eur J Pharm Sci. 2019;140:105070. doi:10.1016/j.ejps.2019.105070
   PubMed Web of Science ®Google Scholar
• Danafar H, Sharafi A, Askarlou S, Manjili HK. Preparation and characterization of PEGylated iron oxide-gold nanoparticles for delivery of sulforaphane and curcumin. Drug Res. 2017;67(12):698–704. doi:10.1055/s-0043-115905
   Google Scholar
• Danafar H, Sharafi A, Kheiri S, Kheiri Manjili H. Co -delivery of sulforaphane and curcumin with PEGylated iron oxide-gold core shell nanoparticles for delivery to breast cancer cell line. Iran J Pharm Sci. 2018;17:480–494.
   Google Scholar
• Zhang B, Zhou X, Miao Y, et al. Effect of phosphatidylcholine on the stability and lipolysis of nanoemulsion drug delivery systems. Int J Pharm. 2020;583:119354. doi:10.1016/j.ijpharm.2020.119354
   PubMedGoogle Scholar
• Sánchez-López E, Guerra M, Dias-Ferreira J, et al. Current applications of nanoemulsions in cancer therapeutics. Nanomaterials. 2019;9(6):821. doi:10.3390/nano9060821
   Web of Science ®Google Scholar
• Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech. 2014;15(3):694–708. doi:10.1208/s12249-014-0088-9
   PubMed Web of Science ®Google Scholar
• Srivastava S, Haider MF, Ahmad A, et al. Exploring nanoemulsions for prostate cancer therapy. Drug Res. 2021;71(08):417–428. doi:10.1055/a-1518-6606
   Web of Science ®Google Scholar
• Zhou L, Zou M, Xu Y, et al. Nano drug delivery system for tumor immunotherapy: next-generation therapeutics. Front Oncol. 2022;12:864301. doi:10.3389/fonc.2022.864301
   PubMed Web of Science ®Google Scholar
• Bazak R, Houri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. J Cancer Res Clin Oncol. 2015;141(5):769–784. doi:10.1007/s00432-014-1767-3
   PubMed Web of Science ®Google Scholar
• Ashique S, Sandhu NK, Chawla V, Chawla PA. Targeted drug delivery: trends and perspectives. Curr Drug Deliv. 2021;18(10):1435–1455. doi:10.2174/1567201818666210609161301
   PubMed Web of Science ®Google Scholar
• He F, Wen N, Xiao D, et al. Aptamer-based targeted drug delivery systems: current potential and challenges. Curr Med Chem. 2020;27(13):2189–2219. doi:10.2174/0929867325666181008142831
   PubMed Web of Science ®Google Scholar
• Lin Y-L, Tsai N-M, Chen C-H, et al. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies. J Nanobiotechnology. 2019;17(1):25. doi:10.1186/s12951-019-0457-3
   PubMedGoogle Scholar
• Saleh T, Soudi T, Shojaosadati SA. Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells. Int J Biol Macromol. 2019;130:109–116. doi:10.1016/j.ijbiomac.2019.02.129
   PubMed Web of Science ®Google Scholar
• Duan D, Wang A, Ni L, et al. Trastuzumab- and Fab′ fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine. 2018;13:1831–1840. doi:10.2147/ijn.S153795
   PubMed Web of Science ®Google Scholar
• Jin H, Pi J, Zhao Y, et al. EGFR-targeting PLGA-PEG nanoparticles as a curcumin delivery system for breast cancer therapy. Nanoscale. 2017;9(42):16365–16374. doi:10.1039/c7nr06898k
   PubMed Web of Science ®Google Scholar
• Ghosh S, Dutta S, Sarkar A, Kundu M, Sil PC. Targeted delivery of curcumin in breast cancer cells via hyaluronic acid modified mesoporous silica nanoparticle to enhance anticancer efficiency. Colloids Surf B Biointerfaces. 2021;197:111404. doi:10.1016/j.colsurfb.2020.111404
   PubMed Web of Science ®Google Scholar
• Soleymani M, Velashjerdi M, Asgari M. Preparation of hyaluronic acid-decorated mixed nanomicelles for targeted delivery of hydrophobic drugs to CD44-overexpressing cancer cells. Int J Pharm. 2021;592:120052. doi:10.1016/j.ijpharm.2020.120052
   PubMedGoogle Scholar
• Sun Y, Li X, Zhang L, et al. Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer. Mol Pharm. 2019;16(3):1140–1155. doi:10.1021/acs.molpharmaceut.8b01123
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang K, Zheng Y, et al. Co-delivery of salinomycin and curcumin for cancer stem cell treatment by inhibition of cell proliferation, cell cycle arrest, and epithelial-mesenchymal transition. Front Chem. 2021;8:601649. doi:10.3389/fchem.2020.601649
   PubMed Web of Science ®Google Scholar
• Mahmoudi R, Ashraf Mirahmadi-Babaheidri S, Delaviz H, et al. RGD peptide-mediated liposomal curcumin targeted delivery to breast cancer cells. J Biomater Appl. 2021;35(7):743–753. doi:10.1177/0885328220949367
   PubMed Web of Science ®Google Scholar
• Hasanpoor Z, Mostafaie A, Nikokar I, Hassan ZM. Curcumin-human serum albumin nanoparticles decorated with PDL1 binding peptide for targeting PDL1-expressing breast cancer cells. Int J Biol Macromol. 2020;159:137–153. doi:10.1016/j.ijbiomac.2020.04.130
   PubMed Web of Science ®Google Scholar
• Lin M, Teng L, Wang Y, Zhang J, Sun X. Curcumin-guided nanotherapy: a lipid-based nanomedicine for targeted drug delivery in breast cancer therapy. Drug Deliv. 2016;23:1420–1425. doi:10.3109/10717544.2015.1066902
   PubMed Web of Science ®Google Scholar
• Esfandiarpour-Boroujeni S, Bagheri-Khoulenjani S, Mirzadeh H, Amanpour S. Fabrication and study of curcumin loaded nanoparticles based on folate-chitosan for breast cancer therapy application. Carbohydr Polym. 2017;168:14–21. doi:10.1016/j.carbpol.2017.03.031
   PubMed Web of Science ®Google Scholar
• Pal K, Laha D, Parida PK, et al. An in vivo study for targeted delivery of curcumin in human triple negative breast carcinoma cells using biocompatible PLGA microspheres conjugated with folic acid. J Nanosci Nanotechnol. 2019;19:3720–3733. doi:10.1166/jnn.2019.16292
   PubMed Web of Science ®Google Scholar
• Cui T, Zhang S, Sun H. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep. 2017;37(2):1253–1260. doi:10.3892/or.2017.5345
   PubMed Web of Science ®Google Scholar
• Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–280. doi:10.1038/ncponc0509
   PubMedGoogle Scholar
• Wartlick H, Michaelis K, Balthasar S, et al. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target. 2004;12(7):461–471. doi:10.1080/10611860400010697
   PubMed Web of Science ®Google Scholar
• Steinhauser I, Spänkuch B, Strebhardt K, Langer K. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials. 2006;27(28):4975–4983. doi:10.1016/j.biomaterials.2006.05.016
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002;8:1172–1181.
   PubMed Web of Science ®Google Scholar
• Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–179. doi:10.1016/j.semcancer.2019.09.015
   PubMed Web of Science ®Google Scholar
• Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem. 2020;20(10):815–834. doi:10.2174/1568026620666200303123102
   PubMed Web of Science ®Google Scholar
• Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3–20. doi:10.1002/1878-0261.12155
   PubMed Web of Science ®Google Scholar
• Singh D, Attri BK, Gill RK, Bariwal J. Review on EGFR inhibitors: critical updates. Mini Rev Med Chem. 2016;16:1134–1166. doi:10.2174/1389557516666160321114917
   PubMed Web of Science ®Google Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64. doi:10.1186/s13045-018-0605-5
   PubMed Web of Science ®Google Scholar
• Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A. CD44: a multifunctional mediator of cancer progression. Biomolecules. 2021;11(12):1850. doi:10.3390/biom11121850
   PubMed Web of Science ®Google Scholar
• Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target. 2015;23(7–8):605–618. doi:10.3109/1061186x.2015.1052072
   PubMed Web of Science ®Google Scholar
• Shan D, Li J, Cai P, et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 2015;5:15–26. doi:10.1007/s13346-014-0210-2
   PubMed Web of Science ®Google Scholar
• Wu PH, Onodera Y, Ichikawa Y, et al. Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells. Int J Nanomedicine. 2017;85:5069–5085. doi:10.1016/j.msec.2017.12.007
   Google Scholar
• Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–571. doi:10.1126/science.7512751
   PubMed Web of Science ®Google Scholar
• Alipour M, Baneshi M, Hosseinkhani S, et al. Recent progress in biomedical applications of RGD-based ligand: from precise cancer theranostics to biomaterial engineering: a systematic review. J Biomed Mater Res A. 2020;108(4):839–850. doi:10.1002/jbm.a.36862
   PubMed Web of Science ®Google Scholar
• Cheng T-M, Chang W-J, Chu H-Y, et al. Nano-strategies targeting the integrin αvβ3 network for cancer therapy. Cells. 2021;10(7):1684. doi:10.3390/cells10071684
   PubMed Web of Science ®Google Scholar
• Luo J, Yao J-F, Deng X-F, et al. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling. J Exp Clin Cancer Res. 2018;37(1):23. doi:10.1186/s13046-018-0694-6
   PubMedGoogle Scholar
• Gato-Cañas M, Zuazo M, Arasanz H, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20(8):1818–1829. doi:10.1016/j.celrep.2017.07.075
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–370. doi:10.1158/2326-6066.Cir-13-0127
   PubMed Web of Science ®Google Scholar
• Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22:174–189. doi:10.1038/s41568-021-00431-4
   PubMed Web of Science ®Google Scholar
• Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. doi:10.3389/fcell.2020.00672
   PubMed Web of Science ®Google Scholar
• Tran-Nguyen VK, Simeon S, Junaid M, Ballester PJ. Structure-based virtual screening for PDL1 dimerizers: evaluating generic scoring functions. Curr Res Struct Biol. 2022;4:206–210. doi:10.1016/j.crstbi.2022.06.002
   PubMedGoogle Scholar
• Mi X, Hu M, Dong M, et al. Folic acid decorated zeolitic imidazolate framework (ZIF-8) loaded with baicalin as a nano-drug delivery system for breast cancer therapy. Int J Nanomedicine. 2021;16:8337–8352. doi:10.2147/ijn.S340764
   PubMed Web of Science ®Google Scholar
• Moazzen S, Dolatkhah R, Tabrizi JS, et al. Folic acid intake and folate status and colorectal cancer risk: a systematic review and meta-analysis. Clin Nutr. 2018;37:1926–1934. doi:10.1016/j.clnu.2017.10.010
   PubMed Web of Science ®Google Scholar
• Qin X, Cui Y, Shen L, et al. Folic acid supplementation and cancer risk: a meta-analysis of randomized controlled trials. Int J Oncol. 2013;133(5):1033–1041. doi:10.1002/ijc.28038
   Google Scholar
• Qian ZM, Tang PL. Mechanisms of iron uptake by mammalian cells. Biochim Biophys Acta. 1995;1269:205–214. doi:10.1016/0167-4889(95)00098-x
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615–1626. doi:10.1016/j.addr.2008.08.005
   PubMed Web of Science ®Google Scholar
• Jefferies WA, Brandon MR, Hunt SV, et al. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162–163. doi:10.1038/312162a0
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410. doi:10.1038/s41467-018-03705-y
   PubMed Web of Science ®Google Scholar
• Uthaman S, Huh KM, Park I-K. Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. Biomater Res. 2018;22(1):22. doi:10.1186/s40824-018-0132-z
   PubMedGoogle Scholar
• Rashidzadeh H, Rezaei SJT, Zamani S, Sarijloo E, Ramazani A. pH-sensitive curcumin conjugated micelles for tumor triggered drug delivery. J Biomater Sci Polym Ed. 2021;32(3):320–336. doi:10.1080/09205063.2020.1833815
   PubMed Web of Science ®Google Scholar
• Ji P, Wang X, Yin J, et al. Selective delivery of curcumin to breast cancer cells by self-targeting apoferritin nanocages with pH-responsive and low toxicity. Drug Deliv. 2022;29(1):986–996. doi:10.1080/10717544.2022.2056662
   PubMed Web of Science ®Google Scholar
• Ghaffari SB, Sarrafzadeh MH, Salami M, Khorramizadeh MR. A pH-sensitive delivery system based on N-succinyl chitosan-ZnO nanoparticles for improving antibacterial and anticancer activities of curcumin. Int J Biol Macromol. 2020;151:428–440. doi:10.1016/j.ijbiomac.2020.02.141
   PubMed Web of Science ®Google Scholar
• Rejinold NS, Thomas RG, Muthiah M, et al. Breast tumor targetable Fe3O4 embedded thermo-responsive nanoparticles for radiofrequency assisted drug delivery. J Biomed Nanotechnol. 2016;12(1):43–55. doi:10.1166/jbn.2016.2135
   PubMed Web of Science ®Google Scholar
• Kulkarni AS, Tapase SR, Kodam KM, Shinde VS. Thermoresponsive pluronic based microgels for controlled release of curcumin against breast cancer cell line. Colloids Surf B Biointerfaces. 2021;205:111834. doi:10.1016/j.colsurfb.2021.111834
   PubMed Web of Science ®Google Scholar
• Howaili F, Özliseli E, Küçüktürkmen B, et al. Stimuli-responsive, plasmonic nanogel for dual delivery of curcumin and photothermal therapy for cancer treatment. Front Chem. 2021;8:602941. doi:10.3389/fchem.2020.602941
   PubMed Web of Science ®Google Scholar
• Sun M, Zhang Y, He Y, et al. Green synthesis of carrier-free curcumin nanodrugs for light-activated breast cancer photodynamic therapy. Colloids Surf B Biointerfaces. 2019;180:313–318. doi:10.1016/j.colsurfb.2019.04.061
   PubMed Web of Science ®Google Scholar
• Khorsandi K, Hosseinzadeh R, Shahidi FK. Photodynamic treatment with anionic nanoclays containing curcumin on human triple-negative breast cancer cells: cellular and biochemical studies. J Cell Biochem. 2019;120(4):4998–5009. doi:10.1002/jcb.27775
   PubMed Web of Science ®Google Scholar
• Nosrati H, Salehiabar M, Kheiri Manjili H, Davaran S, Danafar H. Theranostic nanoparticles based on magnetic nanoparticles: design, preparation, characterization, and evaluation as novel anticancer drug carrier and MRI contrast agent. Drug Dev Ind Pharm. 2018;44(10):1668–1678. doi:10.1080/03639045.2018.1483398
   PubMed Web of Science ®Google Scholar
• Jamshidifar E, Eshrati Yeganeh F, Shayan M, et al. Super magnetic niosomal nanocarrier as a new approach for treatment of breast cancer: a case study on SK-BR-3 and MDA-MB-231 cell lines. Int J Mol Sci. 2021;22(15):7948. doi:10.3390/ijms22157948
   PubMed Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003. doi:10.1038/nmat3776
   PubMed Web of Science ®Google Scholar
• Li Z, Huang J, Wu J. pH-sensitive nanogels for drug delivery in cancer therapy. Biomater Sci. 2021;9(3):574–589. doi:10.1039/d0bm01729a
   PubMed Web of Science ®Google Scholar
• Xiong MH, Bao Y, Yang X-Z, et al. Lipase-sensitive polymeric triple-layered nanogel for “on-demand” drug delivery. J Am Chem Soc. 2012;134(9):4355–4362. doi:10.1021/ja211279u
   PubMed Web of Science ®Google Scholar
• Bordat A, Boissenot T, Nicolas J, Tsapis N. Thermoresponsive polymer nanocarriers for biomedical applications. Adv Drug Deliv Rev. 2019;138:167–192. doi:10.1016/j.addr.2018.10.005
   PubMed Web of Science ®Google Scholar
• Zhou Y, Chen R, Yang H, et al. Light-responsive polymersomes with a charge-switch for targeted drug delivery. J Mater Chem B. 2020;8(4):727–735. doi:10.1039/c9tb02411e
   PubMed Web of Science ®Google Scholar
• Chen H, Ma Y, Wang X, Zha Z. Multifunctional phase-change hollow mesoporous Prussian blue nanoparticles as a NIR light responsive drug co-delivery system to overcome cancer therapeutic resistance. J Mater Chem B. 2017;5(34):7051–7058. doi:10.1039/c7tb01712j
   PubMed Web of Science ®Google Scholar
• Kamel AE, Fadel M, Louis D. Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: development and application in breast cancer cell line. Int J Nanomedicine. 2019;14:5073–5085. doi:10.2147/ijn.S210484
   PubMed Web of Science ®Google Scholar
• Li X, Li W, Wang M, Liao Z. Magnetic nanoparticles for cancer theranostics: advances and prospects. J Control Release. 2021;335:437–448. doi:10.1016/j.jconrel.2021.05.042
   PubMed Web of Science ®Google Scholar
• Liang Y, Duan L, Lu J, Xia J. Engineering exosomes for targeted drug delivery. Theranostics. 2021;11(7):3183–3195. doi:10.7150/thno.52570
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367. doi:10.1126/science.aau6977
   PubMedGoogle Scholar
• Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release. 2015;219:396–405. doi:10.1016/j.jconrel.2015.07.030
   PubMed Web of Science ®Google Scholar
• Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170:15–40. doi:10.1016/j.jconrel.2013.04.020
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1–2):113–142. doi:10.1016/j.ijpharm.2009.10.018
   PubMed Web of Science ®Google Scholar
• Ansari MO, Gauthaman K, Essa A, Bencherif SA, Memic A. Graphene and graphene-based materials in biomedical applications. Curr Med Chem. 2019;26(38):6834–6850. doi:10.2174/0929867326666190705155854
   PubMed Web of Science ®Google Scholar
• Krishna KV, Ménard-Moyon C, Verma S, Bianco A. Graphene-based nanomaterials for nanobiotechnology and biomedical applications. Nanomedicine. 2013;8(10):1669–1688. doi:10.2217/nnm.13.140
   PubMed Web of Science ®Google Scholar
• Mukherjee SP, Bottini M, Fadeel B. Graphene and the immune system: a romance of many dimensions. Front Immunol. 2017;8:673. doi:10.3389/fimmu.2017.00673
   PubMed Web of Science ®Google Scholar
• Mirzaie Z, Reisi-Vanani A, Barati M, Atyabi SM. The drug release kinetics and anticancer activity of the GO/PVA-curcumin nanostructures: the effects of the preparation method and the GO amount. J Pharm Sci. 2021;110(11):3715–3725. doi:10.1016/j.xphs.2021.07.016
   PubMed Web of Science ®Google Scholar
• Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847–6854. doi:10.1158/1078-0432.Ccr-04-0744
   PubMed Web of Science ®Google Scholar
• Cruz–Correa M, Shoskes DA, Sanchez P, et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2006;4(8):1035–1038. doi:10.1016/j.cgh.2006.03.020
   PubMed Web of Science ®Google Scholar
• Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase iia trial. J Nutr. 2019;149(7):1133–1139. doi:10.1093/jn/nxz029
   PubMed Web of Science ®Google Scholar
• Pricci M, Girardi B, Giorgio F, et al. Curcumin and colorectal cancer: from basic to clinical evidences. Int J Mol Sci. 2020;21(7):2364. doi:10.3390/ijms21072364
   PubMed Web of Science ®Google Scholar
• Termini D, Den Hartogh DJ, Jaglanian A, Tsiani E. Curcumin against prostate cancer: current evidence. Biomolecules. 2020;10(11):1536. doi:10.3390/biom10111536
   PubMed Web of Science ®Google Scholar
• Mortezaee K, Salehi E, Mirtavoos‐mahyari H, et al. Mechanisms of apoptosis modulation by curcumin: implications for cancer therapy. J Cell Physiol. 2019;234(8):12537–12550. doi:10.1002/jcp.28122
   PubMed Web of Science ®Google Scholar
• Hassanalilou T, Ghavamzadeh S, Khalili L. Curcumin and gastric cancer: a review on mechanisms of action. J Gastrointest Cancer. 2019;50(2):185–192. doi:10.1007/s12029-018-00186-6
   PubMed Web of Science ®Google Scholar
• Wang L, Wang C, Tao Z, et al. Curcumin derivative WZ35 inhibits tumor cell growth via ROS-YAP-JNK signaling pathway in breast cancer. J Exp Clin Cancer Res. 2019;38(1):460. doi:10.1186/s13046-019-1424-4
   PubMed Web of Science ®Google Scholar
• Yin Y, Tan Y, Wei X, et al. Recent advances of curcumin derivatives in breast cancer. Chem Biodivers. 2022;19(10):e202200485. doi:10.1002/cbdv.202200485
   PubMed Web of Science ®Google Scholar
• Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24. doi:10.3390/ijms24032643
   Web of Science ®Google Scholar
• De Leo V, Maurelli AM, Giotta L, Catucci L. Liposomes containing nanoparticles: preparation and applications. Colloids Surf B Biointerfaces. 2022;218:112737. doi:10.1016/j.colsurfb.2022.112737
   PubMed Web of Science ®Google Scholar
• Forouhari S, Beygi Z, Mansoori Z, et al. Liposomes: ideal drug delivery systems in breast cancer. Biotechnol Appl Biochem. 2022;69(5):1867–1884. doi:10.1002/bab.2253
   PubMed Web of Science ®Google Scholar
• Pandian SRK, Vijayakumar KK, Murugesan S, Kunjiappan S. Liposomes: an emerging carrier for targeting Alzheimer’s and Parkinson’s diseases. Heliyon. 2022;8:e09575. doi:10.1016/j.heliyon.2022.e09575
   PubMed Web of Science ®Google Scholar
• Tang C, McInnes BT. Cascade processes with micellar reaction media: recent advances and future directions. Molecules. 2022;27(17):5611. doi:10.3390/molecules27175611
   PubMed Web of Science ®Google Scholar
• Kaur J, Gulati M, Corrie L, et al. Role of nucleic acid-based polymeric micelles in treating lung diseases. Nanomedicine. 2022;17(25):1951–1960. doi:10.2217/nnm-2022-0260
   PubMed Web of Science ®Google Scholar
• Almajidi YQ, Kadhim MM, Alsaikhan F, et al. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res. 2023;227:115722. doi:10.1016/j.envres.2023.115722
   PubMed Web of Science ®Google Scholar
• Yin Y, Hu B, Yuan X, et al. Nanogel: a versatile nano-delivery system for biomedical applications. Pharmaceutics. 2020;12(3):290. doi:10.3390/pharmaceutics12030290
   PubMed Web of Science ®Google Scholar
• Muraoka D, Harada N, Shiku H, Akiyoshi K. Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. J Control Release. 2022;347:175–182. doi:10.1016/j.jconrel.2022.05.004
   PubMed Web of Science ®Google Scholar
• Zielińska A, Carreiró F, Oliveira AM, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. doi:10.3390/molecules25163731
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang G, Jin S, Xu L, Zhao C-X. Development of high-drug-loading nanoparticles. ChemPlusChem. 2020;85(9):2143–2157. doi:10.1002/cplu.202000496
   PubMed Web of Science ®Google Scholar
• Pandey P, Gulati N, Makhija M, Purohit D, Dureja H. Nanoemulsion: a novel drug delivery approach for enhancement of bioavailability. Recent Pat Nanotechnol. 2020;14(4):276–293. doi:10.2174/1872210514666200604145755
   PubMed Web of Science ®Google Scholar
• Sabjan KB, Munawar SM, Rajendiran D, Vinoji SK, Kasinathan K. Nanoemulsion as oral drug delivery - a review. Curr Drug Res Rev. 2020;12(1):4–15. doi:10.2174/2589977511666191024173508
   PubMedGoogle Scholar
• Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181(1):151–167. doi:10.1016/j.cell.2020.02.001
   PubMed Web of Science ®Google Scholar
• Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905. doi:10.3390/molecules26195905
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
   PubMed Web of Science ®Google Scholar
• Martín Giménez VM, Arya G, Zucchi IA, Galante MJ, Manucha W. Photo-responsive polymeric nanocarriers for target-specific and controlled drug delivery. Soft Matter. 2021;17(38):8577–8584. doi:10.1039/d1sm00999k
   PubMed Web of Science ®Google Scholar
• Heng PWS. Controlled release drug delivery systems. Pharm Dev Technol. 2018;23(9):833. doi:10.1080/10837450.2018.1534376
   PubMed Web of Science ®Google Scholar